Sharpin suppresses β1-integrin activation by complexing with the β1 tail and kindlin-1

Juan Gao¹, Yun Bao¹, Shushu Ge¹, Peisen Sun¹, Jiaojiao Sun¹, Jianmin Liu², Feng Chen¹, Li Han¹, Zhongyuan Cao¹, Jun Qin², Gilbert C. White³,⁴, Zhen Xu¹,³* and Yan-Qing Ma¹,³,⁴*¹

Abstract

Background: Previously sharpin has been identified as an endogenous inhibitor of β1-integrin activation by directly binding to a conserved region in the cytoplasmic tails (CTs) of the integrin β1-associated α subunits.

Methods: Here we employed biochemical approaches and cellular analyses to evaluate the function and molecular mechanism of the sharpin-kindlin-1 complex in regulating β1-integrin activation.

Results: In this study, we found that although the inhibition of sharpin on β1-integrin activation could be confirmed, sharpin had no apparent effect on integrin αIIbβ3 activation in CHO cell system. Notably, a direct interaction between sharpin and the integrin β1 CT was detected, while the interaction of sharpin with the integrin αIIb and the β3 CTs were substantially weaker. Importantly, sharpin was able to inhibit the talin head domain binding to the integrin β1 CT, which can mechanistically contribute to inhibiting β1-integrin activation. Interestingly, we also found that sharpin interacted with kindlin-1, and the interaction between sharpin and the integrin β1 CT was significantly enhanced when kindlin-1 was present. Consistently, we observed that instead of acting as an activator, kindlin-1 actually suppressed the talin head domain mediated β1-integrin activation, indicating that kindlin-1 may facilitate recruitment of sharpin to the integrin β1 CT.

Conclusion: Taken together, our findings suggest that sharpin may complex with both kindlin-1 and the integrin β1 CT to restrict the talin head domain binding, thus inhibiting β1-integrin activation.

Keywords: Sharpin, Kindlin-1, Integrin, Talin

Background

The interaction of cells and extracellular matrix (ECM) in metazoans is tightly regulated by cell adhesion molecules, especially the integrin family members [1]. The integrin-mediated crosstalk between cells and ECM is dynamically regulated by turnover of integrin activation. Dysfunction of integrin activation associates with multiple pathological conditions, such as inflammation, skin fragility, thrombosis and cancer [2, 3]. Integrin activation is a process of conformational changes from a resting state to an active state which allows integrins to bind their extracellular ligands. Integrin activation is precisely modulated, either positively or negatively, through the dialogue between the integrin α/β cytoplasmic tails (CTs) and their intracellular binding partners [4–6].

Among many integrin CT-binding partners, the talin head domain is an essential integrin activator that has been extensively studied [7–9]. At the resting state, the integrin α/β CTs interact with each other and form a membrane-proximal complex [10]. Upon stimulation, the talin head domain can be released and interacts with the conserved NPxY motif and some membrane-proximal residues in the integrin β CT, thus being able to unclasp the integrin α/β CT complex and trigger integrin activation [7, 11, 12]. The kindlin family (kindlin-1, −2 and −3) represents another class of the integrin CT-binding proteins [13–15]. Kindlin and the talin head domain can simultaneously bind to the integrin β CT and cooperatively support integrin activation [16, 17]. Kindlin binds to the second NxxY motif at the C-termini of integrin β CT, but kindlin itself has no capacity to unclasp the
identified as a binding partner of the integrin α oncoprotein features. Interestingly, sharpin has been recentlyκtion and regulating NF-
addition, the role of sharpin in inhibiting integrin activa-
βcan suppress bothbinding of both talin and kindlin to the integrin
αsion [17], it is difficult to explain how sharpin, as an
eously bind to the integrin
βand pathological events [22]. Mice expressing loss-of-function
diphibit multi-organ defects, including chronic inflammation and immunodeficiency [23–25], which are possibly ascribed to the dysfunction of NF-κB activation and apoptotic signaling pathways [22, 26–31]. Sharpin has been found to be highly expressed in many types of tumors [32–35], indicating that it may possess oncogene features. Interestingly, sharpin has been recently identified as a binding partner of the integrin α CT and can suppress both β1- and β2-integrin activation by blocking recruitment of talin and kindlin [32, 36, 37]. In addition, the role of sharpin in inhibiting integrin activation and regulating NF-κB signaling seem to be mutually exclusive [37].

Since the talin head domain and kindlin simultane-
ously bind to the integrin β CT without mutual exclu-
[17], it is difficult to explain how sharpin, as an integran α CT-binding protein, can spatially disrupt binding of both talin and kindlin to the integrin β CT [32]. In this study, by evaluating the regulation of sharpin on the activation of different integrins and testing its interaction with different integrin α/β CTs, we delineate a novel mechanism by which sharpin can specifically suppress integrin activation in an integrin β CT-specific manner.

Methods
Antibodies, plasmids and proteins
Flag antibody (SG4110–16, Shanghai Genomics), 6× histag antibody (SG4110–06, Shanghai Genomics), sharpin antibody (ab174545 and ab69507, Abcam), FAK antibo-
dy (#3283, CST) and Y-FAK antibodies (#3285, CST) were used for immunoblotting; PAC1 antibody (340535, BD Biosciences), 9EG7 antibody (553715, BD Biosciences) and 7E2 antibody (DSHB) were used for FACS analysis. Plasmid of GST-fibronectin type III repeats 9–11 (GST-Fn-III) was kindly provided by David Calderwood [18]. The cDNA of full length sharpin was kindly provide by Ivan Dikic [26], and subcloned into vectors of pET28a, pHis-1, pGST-1 and pGADT7 for different experiments. The CT of integrin α5β1 and integrin α1β3 were subcloned into pGST-1 vector. Kindlin-1 was subcloned into pET31b, pGST-1 and pGBK77 vectors. To express and purify proteins, the expression vectors were transformed into Rosetta DE3 strain and induced to express proteins with 0.4 mM of IPTG. GST-tagged or his-
tagged proteins were purified by Glutathione Sepharose (GE) and Ni-NTA agarose (Qiagen) respectively, according to the manufactures’ protocols. The purified GST-Fn-III protein was further labeled with biotin (EZ-Link™ NHS-Biotin, Thermo Fisher).

Integrin activation assays
Integrin α1β3 activation in CHO cells was measured by flow cytometry using PAC-1 antibody as previously described [38]. In brief, DsRed-fused talin head domain, EGFP-fused kindlin-1 and flag-fused sharpin were co-expressed by transfection in CHO cells that stably express integrin α1β3 (CHO-α1β3). 24 h after transfection, CHO-α1β3 cells were harvested and incubated with PAC-1 (an antibody specific for activated integrin α1β3), followed by incubation with an Alexa-633 labeled secondary antibody. Cells positive for both EGFP and DsRed were selected for measuring the PAC-1 binding by flow cytometry. The PAC-1 binding to CHO-α1β3 cells that were transfected with empty vectors was defined as a basal line. Meanwhile, the expressing levels of integrin α1β3 in transfected CHO-α1β3 cells were measured by an antibody for the integrin α1β3 complex, which were further used to normalize the PAC-1 binding.

Integrin α5β1 activation in CHO cells was evaluated by the GST-fused fibronectin type III repeats 9–11 (GST-Fn-III). Briefly, GST-Fn-III was biotinylated and used to incubate with the transfected CHO cells, followed by staining the cells with an Alexa-647 labeled streptavidin. The GST-Fn-III binding to positively transfected cells was quantified by flow cytometry. The basal binding level was defined with the cells that were transfected only with empty vectors. The specificity of GST-Fn-III binding to β1 integrin on CHO cells was verified by employing a CHO cell line lacking integrin α5β1. Meanwhile, the expression levels of endogenous α5β1 in the transfected CHO cells were also measured and used to normalize the GST-Fn-III binding.

In addition, β1-integrin activation was also evaluated in 3T3 cells by 9EG7 antibody that specifically recog-
nizes the active β1-integron. 3T3 cells were transfected with the indicated regulators and used to incubate with 9EG7, followed by incubation with an Alexa-647 labeled secondary antibody. The transfected cells positive for both EGFP and DsRed were selected for measuring the 9EG7 binding by flow cytometry. Binding of 9EG7 to 3
T3 cells transfected with empty vectors was used as a basal line. Meanwhile, the expressing levels of α5β1-integrin in transfected cells were also measured and used for normalizing the 9EG7 binding.

**Cell adhesion and spreading assays**
Transfected CHO cells were detached and washed three times with serum-free medium. For cell adhesion assay, harvested cells were used to incubate with coated fibronectin at 37 °C for 15 min; for cell spreading assay, the incubating time increased to 60 min. The wells were washed four times with PBS and the adherent cells were fixed with 4% paraformaldehyde. Finally, the adherent cells were imaged by microscopy and further quantified by Image J software.

**GST pull-down assays**
First, GST and GST-tagged integrin CT were incubated with glutathione-Sepharose 4B beads (GE). Then the beads with pre-loaded GST proteins were used to incubate the tested proteins overnight in cold room. After incubation, the beads were extensively washed and proteins bound to the beads were evaluated by SDS-PAGE followed by Coomassie blue staining or immunoblotting. All other GST pull-down experiments described in this study were performed similarly as described above.

**Yeast two-hybrid assays**
The Matchmaker™ Gold yeast two-hybrid system was employed according to the manufacturer’s protocol to determine protein-protein interaction (Clontech). Briefly, sharpin and kindlin-1 (or their mutants) were cloned into pGADT7 and pGBK T7 vectors, respectively, for expressing the fusion proteins of AD-sharpin and BD-kindlin-1. Here AD and BD represent the activation domain and the DNA-binding domain of GAL4. Cell clones grown on SD-2 selection media were further plated on SD-4 selection media that lack tryptophan, leucine, histidine and adenine. Histidine and adenine are selection markers for the AD/BD complex formation. Therefore, growth of the transformed yeast cells on SD-4 media indicates the interaction between sharpin and kindlin-1. In this experiment, Bop1 (BLADE-ON-PETIOLE 1) and Bop2 (BLADE-ON-PETIOLE 2), two known binding molecules, were used as positive controls; and empty vectors were used as negative controls.

**siRNA directed knockdown of endogenous sharpin in cells**
The siRNA duplex specifically targeting sharpin and one non-targeting siRNA control were synthesized (GenePharma, Shanghai). The siRNA sequences were shown as follows: siRNA1 targeting hamster sharpin: 5′-GCACUG GUACGAGAUGCUATT-3′ (sense strand), and 5′-UAGC AUCUGGUACCAGUGCCTT-3′ (antisense strand); siRNA2 targeting hamster sharpin: 5′-GCUCUCAGUGUCCAGC UUATT-3′ (sense strand), and 5′-UAGCUCUGGACAGCUG AGAGCTT-3′ (antisense strand); non-targeting control siRNA: 5′-UCUCGGCAAGUGUCACGUTT-3′ (sense strand), and 5′-CGUGACAGUUCGGGAAGAATT-3′ (antisense strand); siRNAa targeting mouse sharpin: 5′-GCUGAAGCUGCAUAUGUATT-3′ (sense strand), and 5′-UAUUAUGGCGCUUUCCGT T-3′ (antisense strand); siRNAb targeting mouse sharpin: 5′-GCAUCAUGUGGC UCUCAATT-3′ (sense strand), and 5′-AUGAGAGCC ACAUGAGCTT-3′ (antisense strand); and siRNAc targeting mouse sharpin: 5′-CCGGAAAUAGGCUUGUUTT-3′ (sense strand), and 5′-AAACAAGCCUAUUUCGTTT 3′ (antisense strand). Specific siRNA that target sharpin and non-targeting control siRNA were transiently transfected into CHO cells or 3 T3 cells, and their ability to knock down endogenous sharpin was determined by immunoblotting.

**NMR spectroscopy**
Two-dimensional HSQC experiments used to examine the interaction between sharpin and the integrin β CT were performed on Bruker 600MHZ spectrometers equipped with a triple resonance probe at 25 °C in 50 mM Tris, 50 mM NaCl, 1 mM DTT, pH 6.7.

**SPR**
Real time protein-protein interaction was analyzed using a Biacore8K instrument (GE). Purified sharpin protein was coupled to carboxymethyl dextran of CM5 biosensor chips according to the manufacturer’s instruction. Experiments were performed at room temperature in PBS buffer. SPR sensograms were obtained by injecting various concentrations of analytes (the integrin β1 CT and the integrin β3 CT proteins). The chip surfaces were regenerated by injecting a short pulse of glycine (pH 2.0). The resulting sensograms were analyzed in overlay plots using BIA evaluation software.

**Statistical analysis**
Results represent the mean ± SD which are calculated from at least three independent experiments. Statistical significance was calculated using a two-tailed Student’s t-test. More than two groups were compared using the One-way ANOVA post hoc test. A value of P < 0.05 was considered significant.

**Results**
**Sharpin has different effects on regulating integrin α5β1 and integrin αIIbβ3 activation**
Previously it was reported that sharpin could directly bind to a conserved region in the CTs of integrin α1, α2, and α5 subunits and inhibit β1 integrin activation in cancer cells [32]. Since sharpin is widely expressed, it may possibly act as a common inhibitor of activation for
different integrin members. To test this idea, we compared the roles of sharpin in regulating integrin α5β1 and integrin αIIbβ3 activation induced by either the talin head domain alone or the talin head domain plus kindlin-1 in CHO cells that express endogenous integrin α5β1 or CHO-αIIbβ3 cells that stably express exogenous integrin αIIbβ3. The talin head domain, kindlin-1 and sharpin that were fused with DsRed, EGFP and flag tags respectively were transiently expressed in CHO or CHO-αIIbβ3 cells. To ensure the expression of the talin head domain and kindlin-1, transfected cells that were positive for both DsRed and EGFP were selected for functional analyses. Meanwhile, the expression of flag-tagged sharpin was validated by immunoblotting. Integrin activation was evaluated by either the GST-Fn-III binding assay for integrin α5β1 or the PAC-1 binding assay for integrin αIIbβ3. As expected, sharpin significantly suppressed the talin head domain mediated β1-integrin activation (Fig. 1a), which verifies its negative role in regulating β1-integrin activation, as previously described [32]. Interestingly, sharpin failed to suppress the talin head domain mediated integrin αIIbβ3 activation (Fig. 1b). These results suggest that the role of sharpin in regulating integrin activation can be integrin specific. Consistent with the finding from a previous study [18], we also verified that kindlin-1 exhibited distinct functions on regulating integrin α5β1 and αIIbβ3 activation. As shown in Fig. 1a and b, kindlin-1 could inhibit talin head domain mediated integrin α5β1 activation while it adversely enhanced talin head domain mediated integrin αIIbβ3 activation. Importantly, sharpin could further suppress integrin α5β1 activation but had no significant effect on integrin αIIbβ3 activation when it was co-expressed with the talin head domain and kindlin-1. It is worth noting that the observed regulation of sharpin and kindlin-1 on integrin α5β1 activation in CHO cells is not due to the alternately expressed levels of surface β1-integrin since they were very similar across different transfectants (data not shown). Also, the ligand binding was also normalized by the levels of surface expressed integrin. Together, these results suggest that sharpin may regulate integrin activation in an integrin-specific manner.

As we measured by qPCR, sharpin is also endogenously expressed in CHO cells (~0.5% of actin at mRNA levels). We next evaluated the role of endogenous sharpin in regulating integrin α5β1 and integrin αIIbβ3 activation. As shown in Fig. 1c, the expression of endogenous sharpin in CHO cells was significantly suppressed by two siRNA specifically for hamster sharpin. As expected, knocking down endogenous sharpin in CHO cells significantly enhanced the talin head domain induced integrin α5β1 activation (Fig. 1d). Knockdown of endogenous sharpin could substantially reverse the inhibition of kindlin-1 on integrin α5β1 activation, indicating that kindlin-1 may functionally couple with endogenous sharpin in inhibiting integrin α5β1 activation. However, knockdown of endogenous sharpin had no effect on regulating integrin αIIbβ3 activation mediated by the talin head domain or the talin head plus kindlin-1 (Fig. 1e), further verifying that the inhibition of sharpin on integrin activation is specific for integrin α5β1 but not integrin αIIbβ3.

To further specify the regulation of sharpin on conformational changes of β1-integrin, we employed 9EG7, an antibody that specifically recognizes activated β1-integrin of mouse. Here, we utilized mouse 3T3 cells. As shown in Fig. 1f, expression of the talin head domain significantly induced 9EG7 binding in 3T3 cells. Meanwhile, overexpression of sharpin or kindlin-1, or both, significantly reduced the talin head domain induced 9EG7 binding. On the other hand, three siRNA were designed to be used to knock down endogenous sharpin in 3T3 cells (Fig. 1g). When co-expressing the selected sharpin siRNA with the talin head domain or the talin head domain plus kindlin-1, significantly enhanced 9EG7 binding was observed (Fig. 1h). Collectively, these results suggest that sharpin and kindlin-1 can serve as negative regulators of β1-integrin activation in different cells.

**Sharpin directly interacts with the integrin β1 CT and impedes Talin head domain binding**

The effect of specific inhibition of sharpin on integrin α5β1 activation but not integrin αIIbβ3 activation provoked us to explore the possible mechanisms. Since sharpin was previously found to interact with the integrin α CT, we then tested the ability of sharpin bind to the CTs of both integrin α5β1 and integrin αIIbβ3. GST and GST-fused CT proteins of the integrin α5, β1, αIIb and β3 subunits were loaded on Glutathione Sepharose beads and incubated with his-tagged sharpin. After incubation, the beads were extensively washed and sharpin bound to the GST-fused integrin CTs was evaluated by immunoblotting. As shown in Fig. 2a, the integrin β1 CT was able to interact with sharpin. The integrin α5 CT also interacted with sharpin but the binding signal was moderate. Comparatively, the CTs of integrin αIIb and β3 only exhibited minimal binding to sharpin. In addition, we found that the N-terminal region (1–217) but not the C-terminal region (217–387) of sharpin was able to interact with the integrin β1 CT (Fig. 2b). Next, an NMR approach was employed to verify the interaction of sharpin with the integrin β1 and β3 CTs. As shown in Fig. 2c and d, when the N-terminal fragment of sharpin was added to the 15N-labeled integrin β1 CT, significant chemical shift changes occurred, suggesting that these two proteins interact with each other. However, significant chemical shift changes did not appear when the sharpin fragment was added to the 15N-labeled
Fig. 1 (See legend on next page.)
integrin β3 CT. Meanwhile, we also performed SPR experiments by injection of the integrin β1 CT protein or the integrin β3 CT protein and then allowing them to flow over immobilized N-terminal fragment of sharpin. We found that the integrin β1 CT, but not the integrin β3 CT, displayed binding curves by which the binding affinity was calculated at a $K_d$ of $40 \times 10^{-6}$ M (Fig. 2e and f). Together, these results demonstrate that sharpin can substantially interact with the integrin β1 CT while its interaction with the integrin β3 CT is relatively mild. The preference of sharpin binding to the integrin β1 CT may define its functional specificity on inhibiting integrin α5β1.

Because sharpin can interact with the integrin β1 CT and also suppress talin head domain mediated β1-integrin activation, we next tested by pull-down assays if sharpin could affect the talin head domain binding to the integrin β1 CT. As shown in Fig. 2g, sharpin not only interacted with the integrin β1 CT, but also inhibited talin head domain binding to the integrin β1 CT in a dose dependent manner, indicating that sharpin can compete with the talin head domain to bind the integrin β1 CT. As known, the talin head domain interacts with the membrane-proximal NPIY motif in the integrin β1 CT [7, 12, 39, 40]. When the NPIY motif was substituted with AAAA, the mutated integrin β1 CT did not interact with the talin head domain (Fig. 2h), as expected. Importantly, this β1 CT mutant no longer interacted with sharpin either, suggesting that the binding sites of sharpin and the talin head domain in the integrin β1 CT overlap. As a control, the NPIY/AAAA mutations in the integrin β1 CT has no effect on kindlin-1 binding. When the KSAV residues next to the NPIY motif were mutated to AAAA in the integrin β1 CT, the mutated integrin β1 CT still interacted with the talin head domain or sharpin, but failed to interact with kindlin-1 (Fig. 2h). Together, these results show that sharpin may competitively block the talin head domain binding to the integrin β1 CT, by which it suppresses β1-integrin activation.

### Kindlin-1 interacts with sharpin and facilitates recruitment of sharpin to the integrin β1 CT

As demonstrated, kindlin-1 also can inhibit β1-integrin activation (Fig. 1). Interestingly, such an inhibition can be reversed by knocking down endogenous sharpin. The functional correlation between kindlin-1 and sharpin prompted us to test if they can interact with each other. We first employed the yeast two-hybrid system to measure their interaction. As shown in Fig. 3a, the yeast cells transformed with sharpin and kindlin-1 that were respectively fused with the activation domain and the DNA-binding domain of GAL4 were able to grow on selection media, suggesting they interact with each other in yeast cells. However, the interaction of sharpin with kindlin-2 and kindlin-3 was not detectable. Further, we performed pull-down assays and observed a similar binding pattern between sharpin and the kindlin family members, in which sharpin significantly interacted with kindlin-1 while its interaction with kindlin-2 and kindlin-3 were minimal (Fig. 3b). These results suggest that sharpin prefers to interact with kindlin-1 among the kindlin family members.

Identification of the direct interaction between sharpin and kindlin-1 drove us to test if kindlin-1 can facilitate recruitment of sharpin to the integrin β1 CT. As shown in Fig. 3c, in the presence of kindlin-1, the association of sharpin with the integrin β1 CT significantly increased, and concomitantly, the talin head domain binding to the integrin β1 CT dramatically decreased. Importantly, we found that the binding sites of kindlin-1 and the integrin β1 CT in sharpin were different. Kindlin-1 interacted with the C-terminal fragment of sharpin while the integrin β1 CT interacted with the N-terminal fragment of sharpin (Figs. 2b and 3d). Therefore, the mutual interaction of the integrin β1 CT, kindlin-1 and sharpin may
Fig. 2 (See legend on next page.)
enhance the blockage of the talin head domain binding to the integrin β1 CT, by which sharpin and kindlin-1 inhibit β1-integrin activation.

Kindlin-1 interacts with sharpin via its F0 subdomain

Next, we wanted to identify the subdomain in kindlin-1 that is responsible for sharpin binding. Based on a previous test using the yeast two-hybrid system, we found that the N-terminal fragment of kindlin-1 that consists of the F0 and F1 subdomains was able to interact with sharpin (data not shown). Therefore, we focused on this N-terminal fragment of kindlin-1 and verified its interaction with sharpin in the pull-down experiments (Fig. 3e). In addition, we found that kindlin-1 with a deletion of the F0 subdomain failed to interact with sharpin while kindlin-1 missing the F1 subdomain still interacted with sharpin (Fig. 3e), suggesting that the F0 subdomain in kindlin-1 is involved in the interaction with sharpin. Moreover, we found that the kindlin-1 QW/AA mutant that is defective for binding to integrin was still able to interact with sharpin, showing that the binding sites of sharpin and the integrin β1 CT in kindlin-1 are distinct. Moreover, we also verified these binding results using the yeast two-hybrid assay (Fig. 3f). These observations further support the mutual interaction of these three proteins.

In line with the binding results, kindlin-1 with a deletion of the F0 subdomain no longer inhibited the talin head domain mediated β1-integrin activation (Fig. 3g). Although the kindlin-1 QW/AA mutant still had an inhibitory effect on β1-integrin activation, such an inhibition was significantly compromised when compared to wild type kindlin-1 (Fig. 3g), indicating that the inhibition of kindlin-1 on β1-integrin activation relies, at least partially, on its interaction with the integrin β1 CT. Collectively, these results suggest that the inhibition of kindlin-1 on β1-integrin activation may be implemented by facilitating recruitment of sharpin, and subsequently restricting the talin head domain binding to the integrin β1 CT.

Kindlin-1 suppresses β1-integrin mediated cell adhesion and signaling

Based on the above findings that kindlin-1 can suppress β1-integrin activation by recruiting sharpin, we next sought to see if kindlin-1 together sharpin can also affect β1-integrin mediated cell adhesion and spreading. As shown in Fig. 4a and b, overexpression of the talin head domain in CHO cells promoted cell adhesion on immobilized fibronectin; when kindlin-1 was co-expressed, cell adhesion was significantly suppressed; and co-expression of kindlin-1 together with sharpin further diminished cell adhesion. However, late stage cell spreading was only slightly suppressed when kindlin-1 and sharpin were co-expressed with the talin head (Fig. 4c and d). Together, these results demonstrate that kindlin-1 and sharpin significantly affect β1-integrin mediated cell adhesion. Consistently, expression of kindlin-1 or kindlin-1 and sharpin together also reduced FAK activation upon adhesion (Fig. 4e and f). Therefore, these findings show that the kindlin-1-sharpin axis can negatively affect both inside-out and outside-in signaling of β1-integrin.

Discussion

Sharpin, one key component of the linear ubiquitin assembly complex, is involved in regulating NF-kB activation in innate immunity [41]. Interestingly, a previous study showed that sharpin could inhibit β1-integrin activation by directly interacting with the CTs of the integrin β1-associated α subunits (such as α1, α2 and α5) at a conserved membrane-proximal region, and this interaction could disrupt recruitment of talin and kindlin, two key integrin activators, to the integrin β1 CT [32]. In addition, a study from the same group disclosed that sharpin could also interact with the integrin α1 CT and inhibit integrin LFA-1 activation [36]. These studies suggest that sharpin may serve as a common inhibitor for different integrin members since the integrin α CTs
Fig. 3 (See legend on next page.)
share a highly conserved membrane-proximal region. However, in this study, we surprisingly reveal that sharpin may interact with the integrin αIIbβ3 activation in CHO cells and 3T3 cells (Fig. 1). Importantly, we demonstrated that sharpin can interact with the integrin αIIbβ3 CT through different subdomains. Currently, it is unknown whether sharpin can simultaneously interact with these two integrin CTs. Theoretically, possession of two binding sites in the integrin α5β1 CTs for sharpin may facilitate sharpin’s recruitment, and thus facilitate its inhibition on the talin head binding to the β1 CT. To further delineate the functional specificity, the key residues in the integrin β1 CT involved in sharpin binding need to be identified and evaluated in future.

Another novel finding in this study is that sharpin can interact with kindlin-1 (Fig. 3a and b). Interestingly, sharpin preferentially interacts with kindlin-1 but not kindlin-2 or kindlin-3. Because there is no significant interaction between the talin head domain and kindlin [17], kindlin-1, as an integrin binding partner, may recruit sharpin but not the talin head to integrin (Fig. 3c), which can facilitate sharpin binding to the integrin β1 CT and subsequently inhibit the talin head domain binding to the β1 CT in a competitive manner. In fact, kindlin-1 does inhibit the talin head mediated β1 integrin activation (Fig. 1). Since sharpin only minimally interacts with the integrin β3 CT (Fig. 2a, d and f) and has no significant effect on integrin αIIbβ3 activation in CHO-αIIbβ3 cells (Fig. 1b), it seems that the binding capacity of sharpin to the integrin β CT determines its functional consequence on different integrin members. Nonetheless, the kindlin-1 mutant defective for binding to the integrin β1 CT still partially suppresses β1-integrin activation (Fig. 3g), and so does kindlin-2 as demonstrated in another study [18], suggesting that the inhibition of kindlin-1 on β1-integrin activation may also involve additional mechanisms.

Based on our findings, we propose that sharpin may play different roles in regulating integrin α5β1 and αIIbβ3 activation in cells (Fig. 5). Sharpin can be recruited by kindlin-1 and bind to the integrin β1 CT, which is able to block the talin head domain binding to
the β1 CT, thus inhibiting integrin α5β1 activation. Here, kindlin-1 and sharpin cooperatively work with each other in inhibiting integrin α5β1 activation. However, due to the weak interaction between sharpin and the integrin αIIbβ3 CTs, the capacity of sharpin to block the talin head domain binding to the integrin β3 CT can be significantly compromised, which may lead it to be less effective on inhibition of integrin αIIbβ3 activation. Presumably, the expressing levels and the availability of sharpin in different cells may eventually define its role in regulating activation for different integrin members. Interestingly, in a recently published paper, the authors observed that knockdown of endogenous sharpin in human iPS cells led to enhanced fibrinogen binding to differentiated megakaryocytes and platelets [43], suggesting that sharpin actually may be able to inhibit integrin αIIbβ3 activation. Nonetheless, due to the relatively weak interaction of sharpin with the integrin αIIbβ3 CTs as well as kindlin-3, the dominant kindlin member in platelets, a significant inhibition of sharpin on integrin αIIbβ3 activation in platelets through blocking the talin head domain binding to the β3 CT is not expected. However, sharpin may participate to inhibit β1-integrin activation in platelets by directly binding to the integrin β1 CT, which possibly contributes to the observed phenotypes. In addition, other unknown mechanisms might also be involved. Therefore, further studies are required to delineate the role of sharpin in regulating β1-integrin activation and β3-integrin activation in platelets and other cells.

Fig. 4 Kindlin-1 suppresses β1-integrin-mediated cell adhesion and signaling. (A & B) CHO cells expressing the indicated regulators were used to incubate with coated fibronectin for 15 min. After washing and fixation, adherent cells were imaged (a) and counted (b). c CHO cells expressing the talin head (TH) plus empty vectors and TH plus kindlin-1 (K1) and sharpin (SH) were allowed to spread on coated fibronectin for 60 min and then fixed. Representative images of spreading cells were shown. Bar distance was 10 μm. d Spreading areas of cells were calculated with ImageJ software. e Adherent cells on fibronectin were directly lysed for immunoblotting using antibodies for focal adhesion kinase (FAK), tyrosine-phosphorylated FAK (Y-FAK) and actin. f The relative density of Y-FAK signals, as shown in (e), were quantified using ImageJ software. The results represent the mean ± SD of at least 3 experiments. (*, p < 0.05; **, p < 0.01; ***, p < 0.001)
Conclusion
Our study demonstrates that sharpin can directly interact with the integrin β1 CT and kindlin-1 and suppress β1-integrin activation, revealing a novel mechanism in regulating integrin signaling. However, the exact role of sharpin in regulating integrin activation in different cells can be fine-tuned by the stoichiometry/affinity between the participated binding partners.

Abbreviations
CT: Cytoplasmic tail; NMR: Nuclear Magnetic Resonance; SPR: Surface Plasmon Resonance

Acknowledgements
Not applicable.

Authors’ contributions
JG, YB, SG, PS, JS, JL, FC, LH and ZC contributed to acquisition of the data; GCW and JQ contributed to interpretation of the data; YQM, ZX and JG designed to conduct of the experiments, analysis of the data and wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by grants from the NNSFC (31571177, 31770967 and 31500618) and the NIH (HL131654).

Availability of data and materials
Please contact the corresponding authors for all data requests.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Collaborative Research Program for Cell Adhesion Molecules, Shanghai University School of Life Sciences, Shanghai, China. 2Department of Molecular Cardiology, Lerner Research Institute Cleveland Clinic, Cleveland, OH, USA. 3Blood Research Institute, Versthi, 6727 Watertown Plank Road, Milwaukee, WI 53226, USA. 4Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.

Received: 18 June 2019 Accepted: 28 July 2019
Published online: 20 August 2019

References
1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;11:673–87.
2. Diamond MS, Springer TA. The dynamic regulation of integrin adhesiveness. Curr Biol. 1999;4:506–17.
3. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007;25:659–67.
4. Caldenwood DA. Integrin activation. J Cell Sci. 2004;117:657–66.
5. Ye F, Petrich BG. Kindlin: helper, co-activator, or booster of Talin in integrin activation? Curr Opin Hematol. 2011;18:356–60.
6. Bouvard D, Pouwels J, De Franceschi N, Ivaska J. Integrin inactivators: balancing cellular functions in vitro and in vivo. Nat Rev Mol Cell Biol. 2013;14:430–42.
7. Caldenwood DA, Zent R, Grant R, Rees DJ, Hynes RO, Ginsberg MH. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. J Biol Chem. 1999;274:28071–4.
8. Das M, Subbaya IS, Qin J, Plow EF. Mechanisms of Talin-dependent integrin signaling and crosstalk. Biochim.Biophys.Acta. 2014;1838:579–88.
9. Morse EM, Braham NN, Caldenwood DA. Integrin cytoplasmic tail interactions. Biochemistry. 2014;53:1819–20.
10. Qin J, Vinogradova O, Plow EF. Integrin bidirectional signaling: a molecular view. PLoS Biol. 2004;2:e169.
11. Vinogradova O, Vaynberg J, Kong X, Haas TA, Plow EF, Qin J. Membrane-mediated structural transitions at the cytoplasmic face during integrin activation. Proc Natl Acad Sci U S A. 2004;101:4094–9.
12. Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH, Campbell ID. Structural basis of integrin activation by Talin. Cell. 2007;128:171–82.
13. Rognoni E, Ruppert R, Fassler R. The kindlin family: functions, signalling properties and implications for human disease. J Cell Sci. 2016;129:17–27.
14. LaJava H, Plow EF, Wu C. Kindlins: essential regulators of integrin signalling and cell-matrix adhesion. EMBO Rep. 2008;9:1203–8.
15. Plow EF, Qin J, Byzova T. Kindlins: a new view of integrin activation and function with kindlins. Curr Opin Hematol. 2009;16:323–8.
16. Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J Cell Biol. 2008;181:439–46.
17. Bledzka K, Liu J, Xu Z, Perera HD, Yadav SP, Bialkowska K, Qin J, Ma YQ, Plow EF. Spatial coordination of kindlin-2 with Talin head domain in interaction with integrin beta cytoplasmic tails. J Biol Chem. 2012;287:24585–94.
18. Harburger DS, Bouaouina M, Caldenwood DA. Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects. J Biol Chem. 2009;284:11485–97.
19. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008;14:325–30.
20. Montanez E, Ussar S, Schifferer M, Bistol M, Zent R, Moser M, Fassler R. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev. 2008;22:1325–30.
21. Shi X, Ma YQ, Tu Y, Chen K, Wu S, Fukuda K, Qin J, Plow EF, Wu C. The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility. J Biol Chem. 2007;282:20455–66.
22. Brouwer S, Dada LA, Sznajder J. Role of linear ubiquitination in health and disease. Am J Respir Cell Mol Biol. 2016;54:761–8.
23. Seymour RE, Hasham MG, Cox GA, Shultz LD, Hogenesch H, Roopenian DC, Sundberg JP. Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. Genes Immun. 2007;8:8416–21.
24. HogenEsch H, Gijbels MJ, Offerman E, van Hooft J, van Bekkum DW, Zurcher C. A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL/6 mice. Am J Pathol. 1993;143:972–82.
25. Liang Y. Chronic proliferative dermatitis in mice: NFκB activation autoinflammatory disease. Pathol Res Int. 2011;2011:936794.

26. Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, van Wijk SJ, Goswami P, Nagy V, Terzic J, Tokunaga F, Androulidaki A, Nakagawa T, Pasparakis M, Iwai K, Sundberg JP, Schaefer L, Rittinger K, Macek B, Dikic I. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature. 2011;471:637–41.

27. Sasaki K, Iwai K. Roles of linear ubiquitinylation, a crucial regulator of NF-kappaB and cell death, in the immune system. Immunol Rev. 2015;266:173–89.

28. Fujita H, Rahighi S, Akita M, Kato R, Sasaki Y, Wakatsuki S, Iwai K. Mechanism underlying IkappaB kinase activation mediated by the linear ubiquitin chain assembly complex. Mol Cell Biol. 2014;34:1322–35.

29. Bal E, Laplantine E, Hamel Y, Dubosclard V, Boisson B, Pescatore A, Picard C, Hadj-Rabia S, Royer G, Steffann J, Bonnefont JP, Ursini VM, Valeres P, Munich A, Casanova JL, Bodemer C, Weil R, Agou F, Smahi A. Lack of interaction between NEMO and SHARPIN impairs linear ubiquitination and NF-kappaB activation and leads to incontinentia pigmenti. J Allergy Clin Immunol. 2017;140:1671–1682 e1672.

30. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, Tanaka K, Nakano H, Iwai K. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature. 2011;471:633–6.

31. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, Webb AI, Rickard JA, Anderton H, Wong WW, Nachbur U, Gahmberg CG, Salmi M, Ivaska J. SHARPIN is an endogenous inhibitor of beta1-integrin activation. Nat Cell Biol. 2011;13:1315–24.

32. Li J, Lai Y, Cao Y, Du T, Zeng L, Wang G, Chen X, Chen J, Yu Y, Zhang S, Zhang Y, Huang H, Guo Z. SHARPIN overexpression induces tumorigenesis in human prostate cancer LNCaP, DU145 and PC-3 cells via NF-kappaB/ERK/Akt signaling pathway. Med Oncol. 2015;32:444.

33. Zhang Y, Huang H, Zeng L, Wang G, Guo Z. Activation of nuclear factor kappaB pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer. Cancer. 2014;120:2308–18.

34. Bass MD. SHARPINing integrin inhibition. Nat Cell Biol. 2011;13:1315–24.

35. Kasirer-Friede A, Tjahjono W, Eto K, Shattil SJ. SHARPIN at the nexus of integrin, immune, and inflammatory signaling in human platelets. Proc Natl Acad Sci U S A. 2019;116:4983–8.